

Please type a plus sign (+) inside this box → +

SUBSTITUTE for PTO/SB/05 (03-01) Utility Patent Application Transmittal  
Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	21285Y
First Inventor or Application Identifier	
Dai-Shi Su	
Title	NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS
Express Mail Label No.	
EV 321984586 US	

10/614539  
15/707/03  
PTO  
07/07/03

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

- |  |   |
|--|---|
| 1. <input checked="" type="checkbox"/> Fee Transmittal Form<br><i>(Submit an original, and a duplicate for fee processing)</i>   | 6. Nucleotide and/or Amino Acid Sequence Submission<br><i>(if applicable, all necessary)</i>  |
| 2. <input checked="" type="checkbox"/> Specification [ Total Pages 56 ]  | a. <input type="checkbox"/> Computer Readable Form (CRF)  |
| 3. <input type="checkbox"/> Drawing(s) (35 USC 113) [ Total Sheets _____ ]   | b. <input type="checkbox"/> Specification Sequence Listing on:<br>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or<br>ii. <input type="checkbox"/> paper |
| 4. Oath or Declaration   | c. <input type="checkbox"/> Statements verifying identity of above copies   |
| a. <input type="checkbox"/> Newly executed (original or copy)  | 7. <input type="checkbox"/> Assignment papers (cover sheet & document(s))   |
| b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d))<br><i>(for continuation/divisional with Box 14 completed)</i>   | 8. <input type="checkbox"/> 37 CFR 3.73(b) Statement<br><i>(when there is an assignee)</i>  |
| i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b><br><br>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b). | 9. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449   |
| 5. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76  | 10. <input type="checkbox"/> Preliminary Amendment  |
| 14. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: | 11. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503)<br><i>(Should be specifically itemized)</i>  |
| <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP)  | 12. <input type="checkbox"/> Certified Copy of Priority Document(s)<br><i>(if foreign priority is claimed)</i>  |
| Prior application information: Examiner _____  | 13. <input checked="" type="checkbox"/> Other: Unsigned Declaration and Power of Attorney   |

- For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.
15. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number or Bar Code Label	<b>Customer No. 000210</b> (Insert Customer No. or Attach bar code here)		
NAME	Mollie M. Yang		
ADDRESS	Merck & Co., Inc., P. O. Box 2000 - Patent Dept., RY60-30		
CITY	Rahway	STATE	NJ
COUNTRY	USA	TELEPHONE	732-594- 6343
ZIP CODE	07065-0907		
FAX	732-594-4720		

Name	Mollie M. Yang	Registration No. (Attorney/Agent)	32,718
Signature	<i>Mollie</i>	Date	7/7/2003

## EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT July 7, 2003

EXPRESS MAIL NO. EV 321984586 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

MAILED BY *Diane Schepers*

DATE July 7, 2003

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Deposit Acct. 13-2755  
 MERCK & CO., INC.  
 Our Case Docket No. 21285Y

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53(b) is the patent application of Inventor(s):  
 Dai-Shi Su and Mark G. Bock

For: NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS

For	Number Filed	Number Extra	Rate	Basic Fe \$750
Total Claims	20 - 20 =	0 X	\$18	= \$0
Independent Claims	1 - 3 =	0 X	\$84	= \$0
Multiple Dependent Claims*			\$280	=
* Add this fee if application contains any multiple dependent claims, regardless of number.			TOTAL FILING FEE →	\$750

Please charge my Deposit Account No. 13-2755 in the amount of \$ 750. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 13-2755. Duplicate copy of this sheet is enclosed.

Under the provisions of 37 C.F.R. §1.53, this application is being filed without the declaration of each inventor.

Respectfully,

By: Mollie M. Yang

Attorney For Applicant(s)

Reg. No. 32,718

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732) 594-6343

Date: July 7, 2003

EXPRESS MAIL CERTIFICATE	
DATE OF DEPOSIT	<u>July 7, 2003</u>
EXPRESS MAIL NO.	<u>EV 321984586 US</u>
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.	
MAILED BY <u>Dawn Schepler</u> DATE <u>July 7, 2003</u>	

IN DUPLICATE